Anyone trying to source peptides in the UAE quickly runs into two completely separate supply chains. The first is pharmacy retail — Mounjaro, Ozempic, Saxenda, Wegovy, occasional specialty stock like Egrifta — sold through licensed pharmacies after a prescriber visit, registered with the UAE Ministry of Health and Prevention (MoHAP), priced as finished prefilled pens or auto-injectors. The second is research-grade peptide supply — lyophilised vials of retatrutide, tesamorelin, GHK-Cu, BPC-157, TB-500, MOTS-c, semax, NAD+ — sold per milligram of raw peptide, with HPLC certificates of analysis, strictly labelled for in-vitro and research purposes.
The two channels are not substitutes. They are different products with different molecules in many cases, different regulatory routes, different intended uses, and very different economics. Confusing them is the single biggest mistake new UAE researchers make. This guide breaks the distinction down so you can make an informed sourcing decision.
UAE pharmacy products are finished pharmaceutical drugs. They are registered with MoHAP, carry a UAE drug code, are dispensed against a prescription from a DHA, DoH or MoHAP-licensed prescriber, and are intended for therapeutic human use. Mounjaro (tirzepatide), for example, is sold in 2.5, 5, 7.5, 10, 12.5 and 15 mg prefilled pens manufactured by Eli Lilly with a multi-language UAE label and a UAE-specific patient leaflet.
Research-grade peptides are in-vitro reference standards. They are lyophilised raw peptide in a sealed vial, labelled "research use only — not for human consumption," sold for laboratory work including receptor-binding studies, cell-line assays, peptide chemistry method development, and analytical reference. They carry a third-party HPLC certificate of analysis rather than a MoHAP dossier. The legal framework around possession, import and onward sale of research chemicals is distinct from the pharmacy supply chain — UAE researchers should review the UAE peptide import and customs rules for the full picture.
The most common UAE search query that leads here is "retatrutide vs Mounjaro." The honest answer: they are different molecules in different regulatory categories.
| Pharmacy product (UAE) | Research-grade equivalent | Same molecule? |
|---|---|---|
| Mounjaro (tirzepatide) | Retatrutide | No — tirzepatide is a dual GLP-1/GIP agonist; retatrutide is a triple GLP-1/GIP/glucagon agonist |
| Ozempic / Wegovy (semaglutide) | Semaglutide research-grade | Same molecule, different packaging & regulatory route |
| Egrifta (tesamorelin acetate) | Tesamorelin research-grade | Same molecule, finished pen vs lyophilised vial |
| Saxenda (liraglutide) | Liraglutide research-grade | Same molecule, prefilled pen vs vial |
| None — no UAE pharmacy equivalent | BPC-157, TB-500, GHK-Cu, MOTS-c, Semax | Not applicable — research only |
Retatrutide deserves a closer look because of how often it is confused with Mounjaro. The phase 2 trial by Jastreboff and colleagues (NEJM 2023) reported up to 24.2% body-weight reduction at 48 weeks on 12 mg weekly — a deeper response than the 22.5% SURMOUNT-1 result reported by Jastreboff for tirzepatide at 15 mg weekly. Coskun et al. (Cell Metabolism 2022) characterised retatrutide as a balanced triple agonist, with the glucagon arm adding a hepatic energy-expenditure component that tirzepatide lacks. Rosenstock et al. (Lancet 2023) showed similar separation in T2D research populations. They are not the same drug; the science is distinct, and so is the regulatory status — retatrutide remains investigational worldwide and is therefore only available as a research-grade vial.
For tesamorelin the picture is different — the molecule is the same (a GRF(1-44) analog), but Egrifta as a finished pen has a far narrower indication (HIV-associated visceral adipose) and is rarely on UAE pharmacy shelves outside specialty channels. The Falutz 2007 NEJM trial and Stanley 2012 JAMA work that established tesamorelin's metabolic profile both used research-grade lyophilised tesamorelin reconstituted on site. See our deeper tesamorelin UAE research overview for dose-response data.
Pharmacy retail prices in the UAE are quoted per pen or per box. Research-grade vials are quoted per milligram of peptide. Normalising both to a price-per-mg basis is the only fair comparison. Indicative 2026 UAE-market figures (always check live pricing — pharmacy prices in particular shift with MoHAP price reviews):
| Product | Format | Approx. retail (AED) | Peptide content | Price per mg (AED) |
|---|---|---|---|---|
| Mounjaro 5 mg pen | 4 x 5 mg prefilled pen | ~3,200 | 20 mg | ~160 |
| Mounjaro 10 mg pen | 4 x 10 mg prefilled pen | ~3,800 | 40 mg | ~95 |
| Wegovy 1 mg pen | 4-week supply | ~1,300 | ~4 mg | ~325 |
| Egrifta 1 mg vial (where stocked) | Specialty pharmacy | ~5,500/month | ~28 mg (1 mg/day) | ~195 |
| REVIVE Retatrutide 10 mg vial | Lyophilised research vial | Live pricing on product page | 10 mg | Single-digit AED/mg |
| REVIVE Tesamorelin 10 mg vial | Lyophilised research vial | Live pricing on product page | 10 mg | Single-digit AED/mg |
The reason for the order-of-magnitude gap is structural, not arbitrage. Pharmacy retail prices include: MoHAP registration and price-control margin, full clinical trial amortisation, prefilled-pen device engineering, blister and box manufacturing, multi-language regulatory labelling, distributor margin, pharmacy dispensing margin, and prescriber consultation embedded in the supply chain. Research-grade vials strip every one of those layers — you are paying for the peptide itself plus HPLC QC, lyophilisation, vial-and-stopper, cold-chain logistics, and a thin operational margin. That is why the same molecule (semaglutide, tesamorelin, liraglutide) costs 10-30x more in pharmacy format than in research vial format.
REVIVE Peptides operates a temperature-controlled fulfilment hub in Dubai with onward courier links to every emirate. Cold-chain integrity matters more than headline price — a vial that has spent 48 hours in a hot vehicle is degraded peptide regardless of HPLC quality on dispatch (Lee 2018 J Pharm Sci on peptide thermal degradation kinetics).
| Emirate | Delivery window | Cold-chain method | Cut-off for same-day |
|---|---|---|---|
| Dubai (all zones) | Same-day | Insulated courier with ice pack | 2 pm order |
| Abu Dhabi (city + island) | Next-day, often 24h | Overnight insulated courier | 3 pm order |
| Sharjah | Next-day | Insulated courier with ice pack | 3 pm order |
| Ajman, Umm Al Quwain | Next-day | Insulated courier | 3 pm order |
| Ras Al Khaimah, Fujairah | 1-2 working days | Insulated courier with ice pack | 3 pm order |
| Al Ain | 1-2 working days | Insulated courier | 3 pm order |
Currently in stock at the Dubai hub: Retatrutide 5 mg and 10 mg, Tesamorelin 5 mg and 10 mg, GHK-Cu 50 mg and 100 mg, BPC-157 5 mg, TB-500 5 mg, MOTS-c 10 mg, Semax 10 mg, NAD+ 100 mg, and Bacteriostatic Water 3 mL for reconstitution. Each vial ships with a batch-specific HPLC certificate of analysis. Place an order on the UAE peptide catalogue, select your emirate at checkout, and you will see the live cut-off time and delivery window for your address.
Peptides are not small molecules. They are folded polypeptide chains held together by weak bonds and, for some, disulfide bridges. Heat unfolds them. Klausen 2020 reviewed peptide stability across formats and showed that liraglutide and semaglutide degrade measurably above 30 °C within days; tirzepatide carries similar lability. Lyophilised research-grade peptide is more stable than reconstituted solution but still benefits from refrigerated storage and avoidance of heat excursions. UAE ambient temperatures from May to October routinely exceed 40 °C — uninsulated last-mile delivery is not acceptable. REVIVE's cold-chain protocol uses insulated mailers with phase-change ice packs sized to the route duration, and refrigerated storage on arrival at our Dubai hub. See UAE peptide fridge storage guide for post-delivery handling.
Both channels are legitimate within their own regulatory frame. The choice is not "which is better" but "which is appropriate for my use." A clinical patient with a diagnosed condition and a prescription should use the pharmacy channel. A researcher running in-vitro assays or analytical method development should use the research channel.
Retatrutide research interest stems from Jastreboff 2023 (NEJM) and the Rosenstock 2023 (Lancet) T2D data, building on Coskun 2022 (Cell Metab) receptor-pharmacology characterisation. Tirzepatide data sits on Jastreboff 2022 SURMOUNT-1 (NEJM) and Wilding 2021 STEP-1 (NEJM) for the semaglutide comparator. Tesamorelin research rests on Falutz 2007 (NEJM) and Stanley 2012 (JAMA). GLP-1 mechanism literature traces back to Drucker 2006 (Cell Metabolism) and the Müller 2019 (Mol Metab) review. For MASH and metabolic-liver applications, Sanyal 2024 (NEJM) on survodutide provides the comparator. BPC-157 wound-healing literature is largely Sikiric and colleagues; GHK-Cu skin and wound work goes back to Pickart and colleagues; the dermatological side is reviewed in Leyden's body of work on topical actives. Malhotra and colleagues have published broader reviews of GLP-1 cardiometabolic effects. None of this constitutes a human-use recommendation — the citations describe what is known mechanistically and clinically about the molecules themselves.